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MicroRNAs (miRNAs) are involved in post-transcriptional regu-
lation of gene expression through binding to messenger RNAs
(mRNA) thereby promoting mRNA degradation or altered trans-
lation. A single-nucleotide polymorphism (SNP) located within
a miRNA-binding site could thus alter mRNA translation and
inﬂuence cancer risk and treatment response. The common SNPs
located within the 3#-untranslated regions of 20 DNA repair genes
were analysed for putative miRNA-binding sites using bioinfor-
matics algorithms, calculating the difference in Gibbs free bind-
ing energy (DDG) for each wild-type versus variant allele. Seven
SNPs were selected to be genotyped in germ line DNAs both from
a bladder cancer case–control series (752 cases and 704 controls)
and 202 muscle-invasive bladder cancer radiotherapy cases. The
PARP-1 SNP rs8679 was also genotyped in a breast cancer case–
control series (257 cases and 512 controls). Without adjustment
for multiple testing, multivariate analysis demonstrated an asso-
ciation with increased bladder cancer risk with PARP1 rs8679
(Ptrend 5 0.05) while variant homozygotes of PARP1 rs8679 were
also noted to have an increased breast cancer risk (P 5 0.03). In
the radiotherapy cases, carriers of the RAD51 rs7180135 minor
allele had improved cancer-speciﬁc survival (hazard ratio 0.52,
95% conﬁdence interval 0.31–0.87, P 5 0.01). This is the ﬁrst
report of associations between DNA repair gene miRNA-binding
site SNPs with bladder and breast cancer risk and radiotherapy
outcomes. If validated, these ﬁndings may give further insight into
the biology of bladder carcinogenesis, allow testing of the RAD51
SNP as a potential predictive biomarker and also reveal potential
targets for new cancer treatments.
Introduction
In recent years, there has been increasing interest in the role of post-
transcriptional regulation of gene expression by microRNAs (miRNAs)
and their inﬂuence on cancer risk and clinical outcomes. miRNAs are
small endogenous non-coding RNAs of  22–27 nucleotides. These pair
with complementary binding sites located in the 3#-untranslated region
(3#UTR) of messenger RNA (mRNA). Perfect complementation at the
miRNA ‘seed’ site, the second to eighth nucleotide from the 5#-end of
the miRNA, leads to mRNA degradation while imperfect pairing leads
to inhibition of mRNA translation, the end result of both being post-
transcriptional gene silencing (1–3). Based on the importance of seed
pairing, multiple bioinformatics algorithms have been developed in
order to predict miRNA-binding sites in mRNA sequences (4–8).
The efﬁciency of miRNA–mRNA pairing, and consequently gene
expression levels, can be inﬂuenced by a number of factors, including
miRNA expression levels, the presence of single-nucleotide polymor-
phisms (SNPs) in miRNA genes and the presence of SNPs located in
miRNA-binding sites of mRNA 3#UTRs. Differential expression of
miRNAs has been reported in various cancers, including those of
bladder and breast, often linked to alterations in gene copy number
of the miRNA genes (9,10). Polymorphisms in miRNA genes and
miRNA-processing genes have also been found to be associated with
the risk of cancers including breast cancer (11–13). Evolutionarily, Yu
et al. (14) found that there was a negative selection against 3#UTR
SNPs within predicted miRNA seed complementarity sites compared
with other SNPs within the 3#UTR, due to their potentially deleterious
effects. Using bioinformatics tools, studies have found SNPs in pre-
dicted miRNA-binding sites of candidate genes in breast and colorec-
tal cancer that affected miRNA–mRNA binding and were associated
with cancer risk (15,16).
Impaired DNA repair capacity due to DNA repair gene polymor-
phisms is associated with carcinogenesis and increased cancer risk,
particularly for cancers where exposures to tobacco smoke and occu-
pational carcinogens are major risk factors (17,18). Such carcinogens
can cause a variety of DNA adducts including oxidative DNA damage
some of which can lead to somatic mutations in genes, including onco-
genes (19). The pathways involved in the repair of these DNA adducts
are base excision repair (BER), nucleotide excision repair and double
strand break (DSB) repair, mainly by non-homologous end joining
(NHEJ) or homologous recombination.
Case–control studies have shown associations between DNA repair
coding SNPs and bladder cancer susceptibility (20). The International
Consortium on Bladder Cancer has performed a meta-analysis and
pooled analyses of DNA repair gene coding SNPs on bladder cancer
risk, conﬁrming a small but signiﬁcant association for three variants
in ERCC2, NBS1 and XPC (21). In breast cancer, germ line non-
synonymous mutations in the homologous recombination genes,
BRCA1 and BRCA2, have long been linked with familial breast cancer
(22) and studies have reported associations between SNPs in DSB
repair with breast cancer susceptibility (23,24).
DNA repair is also involved in repairing DNA damage from che-
motherapy and radiotherapy treatment of cancer cells. High ERCC1
mRNA and protein expression in bladder cancer cell lines are asso-
ciated with increased sensitivity to cisplatin chemotherapy and ioniz-
ing radiation (25), while low bladder tumour MRE11 protein
expression is associated with worse survival following radiotherapy
treatment(26).However,theroleofgermlinecodingDNArepairSNPs
in predicting cancer survival following radiotherapy treatment has been
less extensively investigated. Several studies have found associations
of ATM, ERCC1 and XRCC1 SNPs with cancer-speciﬁc survival (CSS)
in pancreatic, head and neck and lung cancer (27), whereas Sakano
et al. (28) identiﬁed coding ERCC2 and XRCC1 SNPs potentially
predictive of chemoradiotherapy outcomes in muscle-invasive bladder
cancer patients.
Abbreviations: BER,baseexcisionrepair;CI,conﬁdence interval;CSS,cancer-
speciﬁc survival; DSB, double strand break; MAF, minor allele frequency;
mRNA, messenger RNAs; miRNA, microRNAs; NHEJ, non-homologous end
joining;PCR,polymerasechainreaction;SNP, single-nucleotidepolymorphism;
3#UTR, 3#-untranslated region.
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affect miRNA–mRNA binding and post-transcriptional regulation, thus
inﬂuencing DNA repair capacity and cancer risk in normal somatic
cells and radiotherapy sensitivity and outcome of cancer cells. To ex-
amine these hypotheses, we undertook a two-stage pilot study. First, we
performed a bioinformatics analysis of 20 DNA repair genes, searching
f o rS N P sr e s i d i n gi nt h e3 #UTR, and examined their potential effects on
miRNA-binding in silico. The seven candidate miRNA-binding SNPs
which showed the greatest allele-speciﬁc differential binding were then
genotyped in both a bladder cancer case–control series and also germ
line DNA from patients with muscle invasive bladder cancer cases trea-
ted by radical radiotherapy. PARP1 rs8679 and RAD51 rs7180135 were
found to be associated with bladder cancer risk and radiotherapy out-
comes, respectively. Finally, the PARP1 SNP rs8679 was also assessed
in a breast cancer case–control series.
Materials and methods
Study populations
Local ethical approval for the bladder cancer studies was obtained from the
Leeds (East) Research Ethics Committee, and patients gave written informed
consent. Recruitment of the bladder cancer case–control study population,
comprising 752 bladder cancer cases and 704 controls, has been described
previously (29). The radiotherapy cohort consisted of 202 muscle-invasive
bladder cancer cases treated with external beam radiotherapy (52.5–55 Gy in
20 fractions over 4 weeks) between August 2002 and October 2009 at Cook-
ridge Hospital and St James Institute of Oncology, Leeds, UK. A total of 257
breast cancer cases and 512 controls over the age of 30 years were recruited
between February 1996 and April 2002. Cases were women treated in the
Radiotherapy Department at Lyon-Sud Hospital, Pierre-Be ´nite, France, who
gave written informed consent before participating in the study after local
ethical committee approval had been obtained (30). Controls were age-
matched female blood donors living in the vicinity of the hospital, obtained
from community-based collections of the Regional Blood Transfusion Service.
The health status of these controls was unknown, although any bias from such
an individual having cancer would be expected to favour a null result.
Selection of polymorphisms
Twenty DNA repair genes involved in the BER, nucleotide excision repair,
NHEJ, homologous recombination and DSB signalling pathways were selected
for investigation (Supplementary Table I is available at Carcinogenesis Online).
The methods for the bioinformatics prediction of putative miRNA-binding sites
have been described previously (15). In July 2009, the 3#UTR genomic sequen-
ces for all 20 genes were obtained from the University of California Santa Cruz
genome browser (http://genome.ucsc.edu, 3 January 2012, date last accessed)
and putative miRNA-binding sites within these regions predicted using the
miRBase (4), miRanda (5), Diana-MicroT (6), PicTar (7), TargetScanS (6) and
MicroInspector (8) algorithms. Using the dbSNP (http://www.ncbi.nlm.nih.gov/
projects/SNP, 3 January 2012, date last accessed), BLAST (http://blast.ncbi.nlm.
nih.gov/Blast.cgi?PROGRAM5blastn&BLAST_SPEC5SNP&BLAST_PROG
RAMS5megaBlast&PAGE_TYPE5BlastSearch&SHOW_DEFAULTS5on&
LINK_LOC5dbSNP_homepage, 3 January 2012, date last accessed) and
BLAST-SNP (http://www.ncbi.nlm.nih.gov/SNP/snpblastByChr.html, 28th July
2009, date last accessed) algorithms, common SNPs [minor allele frequency
(MAF).0.10forCaucasians]locatedwithintheseputative miRNA-bindingsites
were identiﬁed. Using miRanda, the Gibbs free energy (DG, expressed in kilo-
joules per mole (kJ/mol)) for both the wild-type and variant alleles for each
identiﬁed SNP was determined, with the difference in DG for the two alleles
(wild-typealleleDG  variantallele DG)calculatedasDDG. Therefore, negative
DDG values indicate weaker miRNA–mRNA binding in the presence of
the variant allele than the wild-type allele (i.e. the wild-type allele DGi sm o r e
negative), whereas positive DDG values mean stronger binding in the presence of
the variant allele (i.e. the variant allele DG is more negative). As more than
one miRNA was predicted to bind to each SNP, thus theoretically increasing
the likelihood of a true miRNA-binding site being present, the sum of all
|DDG|s .3 kJ/mol for each SNP (|DDGtot|) was used to score the impact of that
SNP on miRNA binding. The absolutevalues of DDG( | DDG|) were used to avoid
positive and negative DDG values negating each other. Of the top 10 SNPs with
a| DDGtot| .5 kJ/mol, two SNPs (NBS1 rs1063054 and XPC rs2229090) had
previously been studied in the bladder cancer case–control study (29,31).
The remaining eight SNPs were selected for genotyping.
Genotyping
Genomic DNA samples from the bladder cancer case–control population were
sent for high-throughput Taqman genotyping to Gen-Probe Life Sciences in
West Lothian, Scotland. Blind duplicates from 5% of samples were included to
ensure concordance of genotyping calls. Pre-designed Taqman SNP genotyp-
ing assays (Applied Biosystems) were used for BRCA1 rs12516 and
rs8176318, LIG3 rs4796030, NBS1 rs2735383, PARP1 rs8679 and RAD51
rs7180135. A custom Taqman assay was designed using the ABI assay by
design tool for ATM rs227091 (forward primer: 5#-GGAGAAGAGGA-
AGAACAGAGGGATA-3#, reverse primer: 5#-GGACTAGAGGCTGCTG-
GAAAAG-3#, Reporter 1: VIC-5#-TCACTGCCAGTATCAG-3#, Reporter 2:
FAM-5#-TCACTGCCATTATCAG-3#).Genotypecallinganalysiswasperformed
using SDS 2.2 software (Applied Biosystems).
ATM SNP rs227091 also failed Taqman genotyping and was found to be
located within Alu repeat regions, which was in turn immediately ﬂanked by
a LINE-1 repeat sequence. Therefore, polymerase chain reaction (PCR) pri-
mers within unique sequence ﬂanking the repeat sequences were designed
(forward: 5#-TGCACACAAGCCCATTCTTA-3#, reverse: 5#-AGCTGGGG-
GACAGAGAAATG-3#; Product 842 bp). PCR was carried out using HotStar-
Taq master mix (Qiagen) in 10 ll ﬁnal volume using 40 pmol of each primer
and 10 ng of genomic DNA. Reaction conditions were 95C for 15 min,
36 cycles of 95C, 30 s; 58C3 0s ;7 2 C, 30 s, followed by 72C for 10 min.
DNA sequencing of PCR products, using primers 5#-GGAGTTTCGCTCTTGT-
CACC-3# (rs1137918) and 5#-GTGCAGTGGCATGATCTCAG-3# (rs227091),
was carried out using standard dye terminator chemistry and data were collected
using an Applied Biosystems Genetic Analyser 3130xl.
DNA sequencing was used to conﬁrm the genotype of control samples.
These control samples were run alongside PCR-ampliﬁed samples using the
originalTaqman custom assay (rs227091).Therewas completeconcordance of
genotype by sequencing and Taqman in all samples tested. One microlitre of
1:10 diluted PCR product was dried in a 384-well plate and resuspended in 2 ll
of reaction mix containing 1  Taqman genotyping assay and 1  Taqman
genotyping master mix (Applied Biosystems). Reaction conditions were
50C for 2 min, 95C for 10 min, then 40 cycles of 95C, 15 s; 60C, 60 s.
Taqman ﬂuorophore detection was carried out using an Applied Biosystems
7900 real-time PCR machine.
Another ATM SNP, rs1137918, failed genotyping by Taqman and sequenc-
ing, thus was not investigated further.
In the breast cancer case–control series, PARP1 rs8679 was genotyped using
the above-mentioned pre-designed Taqman assay on 10 ng of genomic DNA
with 2  Taqman genotyping master mix in a ﬁnal volume of 10 ll. The
genotyping PCR conditions were 95C for 10 min, 50 cycles of 95C, 15 s;
60C, 60 s. The region around this SNP was sequenced in 10% of samples
using 10 ng genomic DNA and 10 lM of the forward (5#-TGTGGGAAGAC-
CAAAGGAAG-3#) and reverse (5#-ATAGAGAAGGCATCTGCATTTT-
TAAT-3#) primers in a ﬁnal volume of 20 ll containing 1U of TaqPlatinum
(Invitrogen), 0.2 mM ﬁnal deoxyribonucleotide triphosphates and 1.5 mM ﬁnal
MgCl2. PCR conditions were 95C for 3 min, 45 cycles of 95C, 40 s; 58C,
40 s; 72C, 40 s, 72C for 10 min. Five microlitres of the reaction volume was
puriﬁed using 2 ll ExoSap (USB) and the DNA sequencing reaction was then
carried out using standard dye terminator chemistry on an Applied Biosystems
Genetic Analyser 3130.
Statistical analysis
Statistical analysis was performed using STATA software version 10 (Stata-
Corp, TX) and SAS version 9.1 (SAS, CA). All SNPs were assessed for
Hardy–Weinberg equilibrium of the SNP genotype frequency distribution
in the controls, using a signiﬁcance threshold of P 5 0.05. In the bladder cancer
case–control study, a multivariate logistic regression analysis was performed for
the association of each SNP with bladder cancer risk estimating the odds ratio
(OR)and95%conﬁdenceinterval(95%CI)andadjustingforgender,age (ageat
diagnosis for cases and age at consent for controls), smoking status (ever versus
never) and occupational dye exposure (ever versus never). As the genetic in-
heritance model is unknown, a Cochran-Armitage trend test was deemed to
provide the best power for detecting an association (32). The SNPs showing
a signiﬁcant risk effect were then incorporated into a secondary analysis for the
total number of unfavourable genotype groups carried, adjusting for the same
factors listed above. Logistic regression was used to assess the effect of PARP1
rs8679 in the breast cancer case–control series, the model was adjusted for age
and the dominant gene effect was estimated.
In the muscle-invasive bladder cancer radiotherapy cohort, all SNPs were
assessed as risk factors for CSS considering a dominant gene effect. Kaplan–
Meier andCox proportional hazardmodels were performedadjustingforage at
diagnosis, gender, tumour(WHO stages1–4) and nodal stage (WHO stages 0–2)
and neoadjuvant chemotherapy (received versus not received). CSS was used
as bladder cancer patients treated by radiotherapy tend to be elderly thus more
likely to die of other causes (33).
With 752 cases and 704 controls, the bladder cancer case–control study
had a statistical power of at least 80% for detecting an OR of 1.50 for a MAF
M.T.W.Teo et al.
582of 0.2 at a 1% signiﬁcance level. For 100 cancer-speciﬁc events (assuming
an overall 50% 3 year CSS), the muscle-invasive bladder cancer cohort had
a statistical power of 80% of detecting a hazard ratio of 2.00 in rare homo-
zygotes and heterozygotes combined for a MAF of 0.2 at a 5% signiﬁcance
level.
Results
Bioinformatics predictions
Of the 20 genes,5 genes, ATRX,CETN2,DNA-PK,RAD50 and XRCC1,
had no SNPs located within their 3#UTR, whereas the 3#UTR SNPs in
LIG1 and PCNAwere not sited within a predicted miRNA-binding site.
Of the remainder, there were 21 common SNPs (MAF . 0.10) located
within a predicted miRNA-binding site in 13 genes (Supplementary
Table II is available at Carcinogenesis Online). Ten of these SNPs
had a |DDGtot| .5 kJ/mol. Of these 10 SNPs, 2 had been previously
genotyped in the bladder cancer case–control study, namely NBS1
rs1063054 (29) and XPC rs2229090 (31) and showed no association.
XPC rs2229090 hasalsobeenimputedfromHapmapphase2variantsin
the Nijmegen and Icelandic bladder cancer study populations (B.Kie-
meney, personal communication), with no association found with blad-
der cancer risk (combined OR 5 0.99, 95% CI 5 0.89–1.09, P 5 0.80)
despite this variant having the highest predicted |DDGtot| of 113.27 for
differential miRNA binding. The remaining eight candidate SNPs and
corresponding predicted miRNA-binding sites with a |DDG| .5 kJ/mol
are listed in Table I.
Effects on bladder and breast cancer susceptibility
The bladder cancer and breast cancer study population demographics
have been detailed previously (29,30). ATM rs227091 was success-
fully genotyped by Taqman genotyping of a nested PCR product for
each sample, with full concordance in replicates and an assay failure
rate of 6.25%. The remaining six candidate SNPs were genotyped
with .98% concordance in replicates and an assay failure rate of
,5%. Non-concordant replicates were due to exhaustion of these
samples and so these were dropped from analysis. Hardy–Weinberg
equilibrium for all SNPs was maintained in the controls. In a logistic
regression model for bladder cancer risk including gender, age, smok-
ing status and occupational dye exposure, smoking and occupational
exposures were independent risk factors for bladder cancer (adjusted
OR 5 1.77, 95% CI 5 1.36–2.30, P , 0.001 and adjusted OR 5 1.36,
95% CI 5 1.03–1.79, P 5 0.03, respectively), with no effects seen
for age or gender.
Adjusted logistic regression of the seven SNPs showed that only
PARP1 rs8679 (Ptrend 5 0.05) was associated with increased bladder
cancer risk (Table II). PARP1 rs8679 was also assessed in the breast
cancer case–control study but was not associated with increased
breast cancer risk (Ptrend 5 0.45) though CC homozygotes were noted
to have a greater risk of developing breast cancer compared with TT
(adjusted OR 5 1.90, 95% CI 5 1.05–3.43, p 5 0.03, data not
shown).
Visual inspection of Table II suggests that the dominant model may
better describe the gene effects of PARP1 rs8679. Under a dominant
model (data not shown), PARP1 rs8679 (CT þ CC genotypes) as well
as LIG3 rs4796030 (AC þ AA genotypes) were associated with in-
creased bladder cancer risk (P 5 0.03 and p 5 0.05, respectively).
The combined effects of LIG3 rs4796030 and PARP1 rs8679 was
assessed by collapsing unfavourable genotypes (AC þ AA and CT
þ CC genotypes, respectively) for analysis on bladder cancer risk
(Table III). This demonstrated an additive genotype–dose effect with
the number of unfavourable SNP genotype groups carried (Ptrend 5
0.002). These results,however, shouldbe interpreted with care inview
of the potential application of the incorrect genetic model and the use
of multiple comparisons.
Effects on radiotherapy outcomes
In the muscle-invasive bladder cancer cohort treated by radical radio-
therapy, improved 5-year CSS rates were seen in carriers of at least
one RAD51 rs7180135 minor allele (AG þ GG) compared with com-
mon homozygotes (AA) (Figure 1; 56.2 versus 35.1%, respectively)
in multivariate analysis (adjusted hazard ratio 0.52, 95% CI 5 0.31–
0.87, P 5 0.01) (Table IV).
Discussion
To our knowledge, this is the ﬁrst study demonstrating the effects of
DNA repair gene 3#UTR SNPs within putative miRNA-binding sites
on bladder cancer susceptibility and radiotherapy outcomes. We
found PARP1 rs8679 and possibly LIG3 rs4796030 to be associated
with increased bladder cancer risk, with an additive effect seen with
carriage of both SNPs. In a breast cancer case–control series, PARP1
rs8679 was also associated with increased breast cancer risk in indi-
viduals homozygous for the variant. The candidate SNPs were also
investigated as potential predictive markers of radiotherapy treatment
outcome in muscle-invasivebladder cancer,and we found that carriers
of the RAD51 rs7180135 minor allele had improved 5-year CSS with
an absolute survival advantage at 5 years of 21.1%.
LIG3 is a BER protein and is stabilized by XRCC1. It is recruited
through interactions with PARP1 and XRCC1 to DNA SSBs and
ligates the SSBs generated during short-patch BER. It may also
Table I. Candidate SNPs selected for genotyping in the case–control study
and predicted miRNA binding with DDG .3 kJ/mol
Gene, dbSNP
ID and
allele substitution
MAF Predicted miRNA
binding
DDG
a |DDGtot|
b
LIG3 rs4796030 C.A 0.47 miR-612  5.36 42.17
miR-423-3p  5.23
miR-346  5.17
miR-221  4.49
miR-888   4.36
miR-512-5p  3.90
miR-615-3p  3.70
miR-222  3.44
miR-525-3p  3.30
miR-508-5p  3.22
ATM rs227091 T.C 0.44 miR-217  5.41 38.91
miR-338-3p  5.37
miR-199b-5p  4.79
miR-199a-5p  4.70
miR-24  3.83
miR-593   3.49
miR-134  3.26
miR-196a 3.34
miR-939 4.72
BRCA1 rs12516 C.T 0.36 miR-874  9.92 25.76
miR-324-3p  8.83
miR-623  7.01
BRCA1 rs8176318 G.T 0.35 miR-328  4.10 21.82
miR-565  3.95
miR-149  3.71
miR-146b-3p  3.49
miR-345  3.30
miR-892b  3.27
PARP1 rs8679 T.C 0.17 miR-145  5.71 17.42
miR-105  4.91
miR-630  3.62
miR-302a 3.18
ATM rs1137918 A.G 0.22 miR-615-5p  5.14 12.80
miR-193a-5p  3.69
miR-939 3.97
NBN (NBS1) rs2735383 G.C 0.32 miR-499  4.36 8.70
miR-508-3p  4.34
RAD51 rs7180135 A.G 0.47 miR-197 6.87 6.87
aThe DDG was calculated by deducting the variant DG from the wild-type
DG. A negative DDG indicates decreased binding in the variant compared
with thewild-type, whereas a positive DDG indicates increased binding in the
variant.
b|DDGtot| is the total of the absolute values of DDG( | DDG|).
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PARP1, another BER protein, carries out the poly(ADP-ribosyl)ation
of histones, topoisomerases and DNA repair signalling proteins fol-
lowing DNA damage, resulting in chromatin unwinding and recruit-
ment of DNA repair proteins (35). However, there is also evidence
that PARP1 is involved in other DNA repair pathways and forms part
of an alternative NHEJ repair pathway together with LIG3 and
XRCC1 (36). The total DDG (Table I) for the miRNAs predicted to
bind to LIG3 rs4796030 and PARP1 rs8679 was lower for the variant
alleles (A and C, respectively) compared with the wild-type alleles
(C and T, respectively). Thus, the presence of the variant allele would
be expected to be associated with a decrease in miRNA–mRNA bind-
ing and an increased LIG3 and PARP1 expression. This result is
counter-intuitive as it might be expected that higher levels of DNA
repair enzymes would be associated with increased repair and reduced
cancer risk. However, the over-expression of DNA repair enzymes in
tumours may provide a selective advantage for tumour cell growth
and an over-expression has been associated with a greater risk of
metastasis (37). The additive effect seen in our study of carrying both
LIG3 rs4796030 and PARP1 rs8679 on bladder cancer risk suggests
that either an enhanced BER pathway or the alternative NHEJ path-
way (an error-prone DSB repair pathway compared with classical
NHEJ) predisposes individuals to bladder cancer. PARP1 competes
with Ku (classical NHEJ) for binding to DSB ends and initiating the
alternative NHEJ pathway (38). Increased PARP1 and LIG3 expres-
sion due to LIG3 rs4796030 and PARP1 rs8679 could thus possibly
promote DSB repair via alternative NHEJ over the classical pathway
resulting in more error-prone repair and mutagenesis, with the great-
est inﬂuence seen in carriers of both SNPs.
Of the published literature in bladder cancer on the miRNAs pre-
dicted to bind to LIG3 rs4796030, a pre-miRNA SNP of miR-423 has
previously been associated with increased bladder cancer risk (39),
whereas miR-221 has been reported to be upregulated inbladder cancer
cell lines with miR-221 silencing leading to apoptosis (40). For the
PARP1rs8679SNP,miR-145bindingwaspredictedtohavethegreatest
DDG(  5.71 kJ/mol), with the variant C allele DG being less negative
than the wild-type T allele DG (Table I, a similar proﬁle to that of two
of the other three miRNAs predicted to bind this site) suggesting a
decreased miR-145 binding to the variant PARP1 mRNA 3#UTR and
thusincreasedPARP1expression.Previousstudieshavereporteddown-
regulation of miR-145 expression in bladder cancer (10,41), whereas
transfection of miR-145 in bladder cancer cell lines has a tumour sup-
pressor effect, reducing cell proliferation and inducing apoptotic path-
ways (42). Clearly, there is a need to assess LIG3 and PARP1 protein
levels and miRNA expression proﬁles in breast and bladder tumours to
determine the inﬂuence of these miRNAs on protein expression espe-
cially with current interest in the use of PARP1 inhibitors as a single
agent or as a chemo- or radio-sensitizer in cancer treatment (35).
Table II. Multivariate logistic regression analysis of candidate SNPs on bladder cancer risk
Candidate SNP Observed MAF (reported MAF) Genotype Case Control OR
a (95% CI) Ptrend
b
LIG3 rs4796030 C.A 0.46 (0.47) CC 204 226 1
AC 369 321 1.28 (1.00–1.63) 0.15
AA 160 148 1.21 (0.90–1.64)
ATM rs227091 T.C 0.45 (0.44) TT 201 209 1
CT 320 341 0.92 (0.69–1.21) 0.70
CC 146 148 0.93 (0.69–1.27)
BRCA1 rs12516 C.T 0.33 (0.36) CC 342 292 1
CT 297 318 0.80 (0.64–1.01) 0.43
TT 79 68 1.04 (0.72–1.50)
PARP1 rs8679 T.C 0.21 (0.21) TT 412 424 1
CT 266 214 1.29 (1.02–1.62) 0.05
CC 45 37 1.23 (0.77–1.95)
BRCA1 rs8176318 G.T 0.32 (0.35) GG 349 296 1
GT 303 321 0.80 (0.64–1.00) 0.29
TT 78 70 0.98 (0.68–1.41)
NBS1 rs2735383 G.C 0.32 (0.32) GG 305 313 1
CG 337 308 1.09 (0.87–1.36) 0.27
CC 69 59 1.22 (0.83–1.81)
RAD51 rs7180135 A.G 0.44 (0.47) AA 224 237 1
AG 369 327 1.06 (0.80–1.41) 0.97
GG 145 135 0.90 (0.66–1.21)
aAdjusted for age, gender, smoking status and occupational exposure.
bStatistically signiﬁcant P-values (P   0.05) are in bold.
Table III. Multivariate logistic regression analysis of number of
unfavourable LIG3 rs4796030 and PARP1 rs8679 SNP genotypes on bladder
cancer risk
Number of
unfavourable genotypes
carried
a
Case Control OR
b (95% CI) Ptrend
c
0 115 145 1 0.002
1 375 352 1.33 (0.99–1.78)
2 220 169 1.65 (1.20–2.29)
aUnfavourable genotypes deﬁned as LIG3 rs4796030 AC þ AA and PARP1
rs8679 CT þ CC.
bAdjusted for age, gender, smoking status and occupational exposure.
cStatistically signiﬁcant P-values (P   0.05) are in bold.
Fig. 1. Kaplan–Meier survival curves of CSS in combined heterozygotes
and rare homozygotes of RAD51 rs7180135 (AG þ GG) versus wild-type
(AA).
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584Several association studies have identiﬁed 3#UTR SNPs in candi-
date genes for their inﬂuence on cancer risk with signiﬁcant SNPs
then investigated for putative miRNA-binding sites (43,44). In blad-
der cancer, we previously found an association for the DSB repair
MRE11 rs2155209 3#UTR SNP with increased bladder cancer risk
(29). In the current study, this variant is predicted to be within the
binding sites for miR-584 and miR-744 but the minor allele is pre-
dicted to alter the DDG for either miRNA by ,1 kJ/mol (Supplemen-
tary Table II is available at Carcinogenesis Online), thus the
mechanism underlying this association remains to be determined.
Several studies have used in silico methods to identify SNPs located
within predicted miRNA-binding sites then evaluated their inﬂuence
on cancer susceptibility (15,16,45). Using the bioinformatics analysis
methods described above, Landi et al. (15) reported an association
between 3#UTR SNPs in predicted miRNA-binding sites and cancer
risk, showing that CD86 3#UTR SNP rs17281995 was predicted to
affect the binding of four miRNAs and was associated with increased
colorectal cancer risk (15). Chin et al. (45) demonstrated that KRAS
3#UTR SNP rs712 was sited within a let-7-binding site and was
associated with increased lung cancer risk and also using a luciferase
with KRAS 3#UTR reporter assay, resulted in increased luciferase
activity compared with wild-type (45). Nicoloso et al. (16) also found
two predicted miRNA-binding site SNPs located within the coding
regions of BRCA1 and TGFR1 that affected post-transcriptional
miRNA regulation (16), indicating possible miRNA-binding sites
within the 5#UTR and coding regions of our candidate genes.
The role of miRNA-binding site polymorphisms as prognostic
markers was highlighted by Brendle et al. (46). They identiﬁed a
3#UTR SNP within the ITGB4 gene associated with worse breast
cancer survival and oestrogen receptor-negative tumours (46). As ion-
izing radiation from radiotherapy causes cancer cell death by inducing
DNA damage, the candidate SNPs were thus investigated as potential
predictive markers of radiotherapy treatment outcomes in muscle-
invasivebladdercancer.WefoundtheRAD51rs7180135G minor allele
to be associated with improved survival. miR-197 is predicted to bind
more strongly to the G allele (DDG 6.87 kJ/mol) resulting in the re-
duction of RAD51 expression. RAD51 is involved in DSB homologous
recombination repair; thus in tumours, alteration of RAD51 expression
could potentiate tumour radiosensitization. Low tumour RAD51 mRNA
expression has previously been associated with lower local recurrence
and improved survival following adjuvant chemotherapy and radiother-
apy treatment in breast cancer (47). Differential expression of miR-197
has been reported in several cancers with up-regulation seen in squa-
mous cell carcinoma of the tongue and male breast carcinoma and
down-regulation in gastric cancer (48–50). Plasma miR-197 levels have
also been proposed as a potential diagnostic biomarker having been
reported to be elevated in lung cancer (51). In human colon cancer cell
lines, miR-197 expression levels were down-regulated following oxali-
platin and 5-ﬂuorouracil treatment (52). In response to DNA damage,
the effect of miR-197 down-regulation in cancer cells could thus be to
increase DNA repair by increasing RAD51 expression. Our results
suggest that the RAD51 rs7180135 genotype and its possible effects
on miR-197-mRNA-binding may predict tumour radiosensitivity and
radiotherapy outcomes in bladder cancer. If successfully validated, this
might be used clinically as a predictive marker of radiotherapy out-
come. Future studies of miR-197 as a therapeutic target to improve
radiotherapy outcomes would also be worthwhile.
In this study, we have examined seven polymorphisms for associa-
tions, using multiple genetic models, with risk of bladder cancer and
cause-speciﬁc mortality following radiotherapy. One of these polymor-
phisms was further tested for association with breast cancer risk. Given
the complex correlation structure between these multiple tests, it is
difﬁcult to calculate the number of tests carried out in order to correct
for multiple comparisons using a method such as the Bonferroni cor-
rection. If we simply correct for the number of SNPs genotyped, seven,
the Bonferroni-corrected signiﬁcance threshold would be 0.007. As
such none of the associations observed would remain statistically sig-
niﬁcant. Similarly, the SNPs were all chosen due to their prior pro-
bability of functional signiﬁcance, due to their inﬂuence on miRNA
binding. However, the magnitude of this prior probability is also difﬁ-
cult to estimate for use in correction methods such as the false-positive
report probability (53). Due to the subjectivity of the assumptions
necessary for these corrections, we have chosen to not formally correct
the P-values reported and thus acknowledge that the results should be
interpreted with caution with the possibility of false-positive discovery.
In conclusion, we have examined the 3#UTR of 20 candidate DNA
repair genes using in silico methods to identify SNPs that potentially
affect miRNA binding. We have found associations between PARP1
rs8679 and increased bladder cancer and breast cancer risk and
RAD51 rs7180135 and improved CSS following radiotherapy treat-
ment in muscle-invasive bladder cancer. While the ﬁrst of its kind in
bladder cancer, our study also corroborates the work of others in other
tumour types, investigating the association of miRNA-binding site
SNPs and cancer susceptibility (15,16,45). If our ﬁndings can be
successfully validated in further series and functional effects demon-
strated in suitable assays, they may give further insight into the
biology of bladder carcinogenesis, allow testing of the RAD51 SNP
as a potential predictive biomarker and also reveal potential targets for
new cancer treatments.
Supplementary material
Supplementary Tables 1 and II can be found at http://
carcin.oxfordjournals.org/
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